Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQR9I8)

Drug Name
G-202 Drug Info
Synonyms UNII-Q032I35QMX; Q032I35QMX; 1245732-48-2; Mipsagargin [USAN:INN]; Mipsagargin (USAN/INN); CHEMBL3989865; DB11813; D10715
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
PubChem CID
24772106
CAS Number
CAS 1245732-48-2
TTD Drug ID
DMQR9I8

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate carboxypeptidase II (GCPII) TT9G4N0 FOLH1_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glutamate carboxypeptidase II (GCPII) DTT FOLH1 6.894 4.758 5.651 9.837
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Adenocarcinoma
ICD Disease Classification 2D40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glutamate carboxypeptidase II (GCPII) DTT FOLH1 1.40E-09 2.08 2.21
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01777594) Study of G-202 as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma. U.S. National Institutes of Health.
3 National Cancer Institute Drug Dictionary (drug id 666090).